AIM ImmunoTech Provides First Quarter 2021 Business Update

by Barry101 | May 18, 2021 | Press Release, Uncategorized

OCALA, Fla., May 18, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.   As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to...

AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo

by Barry101 | May 3, 2021 | Press Release, Uncategorized

OCALA, Fla., May 03, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant...

AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

by Barry101 | Apr 27, 2021 | Press Release, Uncategorized

OCALA, Fla., April 27, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting...

AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

by Barry101 | Apr 7, 2021 | Press Release, Uncategorized

OCALA, Fla., April 07, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events,...

AIM ImmunoTech Reports 2020 Year-End Financial Results

by Barry101 | Mar 31, 2021 | Press Release, Uncategorized

OCALA, Fla., March 31, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.2020 Financial HighlightsAs of December 31, 2020, AIM had cash, cash equivalents and...

AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COVID-19

by Barry101 | Mar 22, 2021 | Press Release, Uncategorized

OCALA, Fla., March 22, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park’s ongoing Phase...